The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSPE.L Regulatory News (SPE)

  • There is currently no data for SPE

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Accolade Release 10.2

21 Jan 2016 08:29

RNS Number : 5678M
Sopheon PLC
21 January 2016
 

SOPHEON PLC

("Sopheon" or the "Company")

 

Accolade Release 10.2 Increases Innovation Project Velocity

 

Sopheon, the international provider of software, expertise, and best practices for Enterprise Innovation Performance, announces today the latest version of its Accolade Enterprise Innovation Management solution.

Accelerated innovation velocity: Time is money, and creating new technologies and bringing new products to market more quickly means increased profits and revenues. Intelligent automation and smart workflows in Accolade 10.2 reduce the amount of manual intervention required for innovation processes to keep moving forward at pace, and enhance the flow of communication and collaboration across even highly dispersed work teams. Companies can use these capabilities to accelerate project velocity and time to market, helping them move with greater speed and focus towards the next innovation milestone.

A Sopheon customer-a multi-billion dollar chemical company and early reviewer of Accolade release 10.2-plans to significantly reduce time-lags and human error in the decision-making process by having their Accolade system automatically move projects to the next stage in the development cycle. These migrations will be triggered when pre-defined key performance indicators are met and/or when all relevant stakeholders have given approval in Accolade.

More focused and efficient user experience: This release is another step forward in raising the industry standard on user engagement in the innovation process by bringing critical documents, information and data into core innovation workflows, enabling people to complete their work more efficiently and with less effort.

Don Sarno, Chief Operating Officer at Sopheon says, "CEOs understand that speed-to-market and agility are competencies critical to surviving in the new norm of competitive markets. With Accolade release 10.2, we continue to provide a tight alignment and personal connection between team member activities and company value, in addition to reducing wasted cycles from the top of the organization to the front line."

 

Sopheon® and Accolade® are trademarks of Sopheon.

 

 

For further information contact:

Barry Mence, Chairman

Sopheon plc

+ 44 (0) 1276 919 560

Arif Karimjee, CFO

Sopheon plc

+ 44 (0) 1276 919 560

Ed Frisby / Carl Holmes (corporate finance)

Mia Gardener (corporate broking)

finnCap

+ 44 (0) 20 7220 0500

 

 

About Sopheon. Sopheon (LSE: SPE) partners with customers to provide complete enterprise innovation management solutions including software, expertise, and best practices, that enable them to achieve exceptional long-term revenue growth and profitability. Sopheon's Accolade solution provides unique, fully-integrated coverage for the entire innovation management and new product development lifecycle, including strategic innovation planning, roadmapping, idea and concept development, process and project management, portfolio management and resource planning. Sopheon's solutions have been implemented by over 200 customers with over 60,000 users in over 50 countries. Sopheon is listed on AIM, operated by the London Stock Exchange. For more information, please visit www.sopheon.com.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
NRAAKDDBFBKKFDB
Date   Source Headline
24th Jul 20199:05 amRNSSecond Price Monitoring Extn
24th Jul 20199:00 amRNSPrice Monitoring Extension
24th Jul 20197:00 amRNSTrading Update
13th Jun 20191:06 pmRNSResult of AGM
13th Jun 20197:00 amRNSAccolade 12.3
13th Jun 20197:00 amRNSAGM Statement
11th Jun 20191:32 pmRNSIssue of Equity
15th May 20197:00 amRNSSopheon Expands Customer Foothold in Asia
13th May 20199:14 amRNSIssue of Equity
28th Mar 20197:00 amRNSSopheon and National Foods Limited Partnership
21st Mar 20197:00 amRNSFinal Results
5th Feb 20197:00 amRNSIssue of Equity
29th Jan 20197:00 amRNSTrading Update
24th Jan 20194:41 pmRNSSecond Price Monitoring Extn
24th Jan 20194:35 pmRNSPrice Monitoring Extension
17th Jan 20197:00 amRNSAccolade Release 12.2
11th Jan 20197:00 amRNSTrading Update
8th Jan 20197:00 amRNSSopheon Partners with The Hershey Company
18th Dec 20182:53 pmRNSIssue of Equity
16th Nov 201812:54 pmRNSIssue of Equity
31st Oct 20185:18 pmRNSIssue of Equity
23rd Oct 20187:00 amRNSSopheon Awarded The Nature's Bounty Co. Business
8th Oct 20189:05 amRNSSecond Price Monitoring Extn
8th Oct 20189:00 amRNSPrice Monitoring Extension
8th Oct 20187:00 amRNSTrading Update
10th Sep 20187:00 amRNSDoosan Bobcat Awards Sopheon Innovation Contract
7th Sep 20185:48 pmRNSIssue of Equity
29th Aug 20183:54 pmRNSIssue of Equity & Holdings in Company
28th Aug 20187:00 amRNSAccolade Enterprise Innovation Management
23rd Aug 20187:00 amRNSHalf Yearly Report
19th Jul 201811:05 amRNSSecond Price Monitoring Extn
19th Jul 201811:00 amRNSPrice Monitoring Extension
19th Jul 20187:00 amRNSTrading Update
5th Jul 20189:40 amRNSGrant of Options / PDMR Dealing
3rd Jul 20189:24 amRNSIssue of Equity
13th Jun 20182:37 pmRNSIssue of Equity
7th Jun 201812:09 pmRNSResult of AGM
7th Jun 20187:00 amRNSAGM Statement
31st May 20182:56 pmRNSIssue of Equity
17th May 20188:01 amRNSResult of Secondary Placing
16th May 20183:05 pmRNSProposed Secondary Placing
15th May 20187:00 amRNSIssue of Equity
27th Apr 20183:59 pmRNSIssue of Equity
29th Mar 20187:00 amRNSAccolade Release 12.0
23rd Mar 20183:56 pmRNSIssue of Equity
23rd Mar 20187:00 amRNSIssue of Equity
22nd Mar 20187:00 amRNSFinal Results
20th Feb 20187:00 amRNSSopheon named in Annual Reader's Choice List
12th Feb 20189:24 amRNSGrant of Options / PDMR dealing
5th Feb 20183:35 pmRNSIssue of Equity

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.